在TACR1基因多态性中确定新辅助化疗病理完整反应的潜在调解者:对乳腺癌患者的研究
Marziyeh Ghorbani1, Soha Namazi2, Mehdi Dehghani3
1Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Karafarin St., Shiraz, 7146864685, Iran.
Breast cancer research and treatment
|March 13, 2025
概括
神经基因-1受体 (NK-1R) 基因的遗传变异会影响乳腺癌的化学抵抗. rs17010664变体与减少病理完整反应 (pCR) 和潜在的治疗点相关.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 截断的神经-1受体 (NK-1R) 和物质P (SP) 涉及乳腺癌化学抵抗,扩散,血管生成和转移.
- 在瘤细胞中观察到切断的NK-1R异型的过度表达,导致治疗失败.
研究的目的:
- 为了研究神经素-1受体 (NK-1R) 编码基因多态化对截断的NK-1R水平的影响.
- 评估接受新辅助化疗的乳腺癌患者中这些多态和化疗抵抗,病理完整反应 (pCR) 之间的关联.
主要方法:
- 在153名乳腺癌患者中使用实时PCR-HRMA对TACR1基因中的18个标记单核酸多态 (SNP) 的基因定型.
- 统计分析包括单变量分析,与共变量调整的逻辑回归,并进行 permutation 测试以评估与 pCR 的关联.
主要成果:
- 瘤III级和I阶段与pCR的更高概率有关.
- 在各种遗传模型下,SNP rs17010664,rs6715729和rs3771869显示出与pCR实现的显著关联.
结论:
- 该rs17010664 C等位基因可能会增强TACR1的最后一个外子拼接,增加截断的NK-1R产量,导致化学抵抗和减少PCR.
- 用NK-1R抗剂准SP/截断的NK-1R轴可能是克服化疗抵抗的治疗策略.
- 需要进一步的研究来确定NK-1R抗剂作为潜在的抗瘤剂的最佳剂量.
更多相关视频
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.4K
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
370
相关概念视频
Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
